Adj. Dyn. Marker-adjusted Personalized Therapy Comparing Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk HR+/HER2- EBC

  • STATUS
    Recruiting
  • End date
    Dec 3, 2027
  • participants needed
    1250
  • sponsor
    West German Study Group
Send
Updated on 3 September 2021
See if I qualify

Summary

Patients with breast cancer, who have completed first line therapy (e.g., radiotherapy, chemotherapy, surgery), and who have to be identified with having a high risk of recurrence of cancer, will be eligible for the study. This patient group is currently offered a standard of care chemotherapy plus endocrine therapy (ET). The study investigates whether the patient group with high-risk early breast cancer benefits from treatment with the medication abemaciclib in combination with ET compared to ET alone.

Description

The WSG ADAPT trial program is one of the first new generation trials addressing the issue of individualization of (neo)-adjuvant decision-making in early breast cancer (EBC) in a subtype-specific manner. The first WSG ADAPT umbrella trial (NCT01779206) aimed to establish early predictive molecular surrogate markers for response after a short 3-week induction treatment.

The goals of the WSG ADAPT trial program - early response assessment and subtype-specific therapy tailoring to those patients who are most likely to benefit - have contributed to the positive national and international feedback regarding the ADAPT-concept as a whole.

The aim of this ADAPTlate phase-III-trial is to gain further knowledge of the group of patients at high risk for disease recurrence, who have completed definite locoregional therapy (with or without neoadjuvant or adjuvant chemotherapy). This patient group is currently offered an adjuvant chemotherapy plus endocrine therapy. Yet, the high-risk population only receives suboptimum benefit from standard ET and often develops resistance against ET at time of recurrence. With ADAPTlate it is planned to investigate if the high-risk patient group identified during the screening phase derives additional benefit from treatment with abemaciclib in combination with ET compared to ET alone.

Details
Condition Breast Cancer Female
Treatment Abemaciclib 50 MG; 150mg 1-0-1 per os
Clinical Study IdentifierNCT04565054
SponsorWest German Study Group
Last Modified on3 September 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

Prior to REGISTRATION
Written informed consent prior to any study procedures (outcomes of standard-of-care procedures performed before signing of informed consent by the patient but within allowed screening period can be used for screening of patient)
Female
18 years of age. 4a. EITHER: (Post)menopausal status at the time of initiation of adjuvant study medication
patient underwent bilateral oophorectomy, or
age 60, or
age < 60 and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, or ovarian suppression) and/or FSH and estradiol in the postmenopausal range per local normal range
b. OR: Pre-menopausal patients
confirmed negative serum or urine pregnancy test (-hCG) before starting study treatment, or
patient has had a hysterectomy. 5. Histologically confirmed diagnosis of primary estrogen-receptor positive and/or progesterone-receptor positive early breast cancer by local laboratory. In case the receptor status from local pathology is unclear a central pathology review is obligatory. Results must be known prior to randomization. 6. Patient has HER2-negative breast cancer defined as
a negative in-situ hybridization test or an IHC status of 0, 1+, or 2+
if IHC is 2+, a negative in-situ hybridization (FISH, CISH, or SISH) test is required (based on the analyzed tissue sample at initial diagnosis by a local laboratory). 7. Completed local therapy of breast cancer according to current guidelines. 8. Completed or ongoing endocrine therapy for 2-6 years after primary diagnosis without any signs of distant or local relapse as well secondary malignancy
a. Known high clinical risk, defined as either one of the following criteria
c/pN 2-3
pN 0-1 and high CTS5 score
cN 1 or G3 tumor and non-pCR after neoadjuvant chemotherapy
pN0-1 and G3 with Ki-67 pre-treatment > 40%; OR 9b. Known high genomic risk, defined as either one of the following criteria
c/pN 1 with RS (Oncotype Dx) >18
c/pN 0 with RS >25
high risk by PROSIGNA (score > 60 in N 0 and >40 in N+) or EPclin (Score >3.3287), or MammaPrint within clinical routine; OR
In case the tumor is of intermediate clinical risk, but genomic risk is not
known at
registration
c. Intermediate clinical and unknown genomic risk c/pN 0-1 in luminal-B-like
tumor (G3 and/or Ki-67 pre-treatment 20%), AND
RS >18 (Oncotype Dx in screening phase) in patients with c/pN 1, or
RS >25 (Oncotype Dx in screening phase) in patients with c/pN 0. B. Prior to RANDOMIZATION in the study 10. No clinical evidence of distant metastasis (confirmation recommended prior to randomization by CT thorax / abdomen, chest X-ray, liver ultrasound, bone scan, or PET-CT, respectively). 11. Patient has available tumor tissue from primary diagnostic biopsy. 12. No contraindication for adjuvant ET. 13. Eastern Cooperative Oncology Group (ECOG) performance status 0-1. 14. Patient has adequate bone marrow and organ function as defined by the following laboratory values
absolute neutrophil count 1.5 109/L (without administration of any growth stimulation factors within 30 days prior to inclusion)
platelets 100 109/L
hemoglobin 8.0 g/dL (without any RBC transfusion within 30 days prior to inclusion)
total bilirubin <1.5 ULN, except for patients with Gilbert's Syndrome who may only be included if the total bilirubin is 2.0 ULN or direct bilirubin within normal ranges
aspartate transaminase (AST) < 3 ULN
alanine transaminase (ALT) < 3 ULN
serum creatinine 1.5 x ULN. 15. Ability to swallow abemaciclib tablets or to administer other study medication, respectively. 16. Ability to communicate with the investigator and comply with study procedures. 17. Willing to receive therapy by the clinical site, as required by the protocol

Exclusion Criteria

Patients eligible for inclusion in this study must not meet any of the
following criteria
Patient with distant metastases of breast cancer beyond regional lymph nodes
Previously received CDK 4/6 inhibitor
Patient with a known hypersensitivity to any of the excipients of abemaciclib or standard-of-care endocrine therapy
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects
Patient has not recovered from clinical and laboratory acute toxicities related to prior anticancer therapies to NCI CTCAE version 5.0 Grade 1 (polyneuropathy 2 is allowed)
Patient has a concurrent malignancy or non-breast malignancy within 5 years prior to randomization
Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., uncontrolled ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small-bowel resection)
Patient has any active systemic bacterial infection (requiring intravenous antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment
Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigators judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study, or compromise compliance with the protocol (e.g., interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea, etc.)
Patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest
Patient is currently receiving any of the following substances, which cannot be discontinued 7 days prior to day 1 of study treatment
concomitant medications and herbal supplements, that are strong inducers or inhibitors of CYP3A4
Participation in a prior investigational study within 30 days prior to enrollment
Not able to understand and to comply with study instructions and requirements
Pregnant or nursing (lactating) woman
Woman of child-bearing potential defined as woman physiologically capable of becoming pregnant, unless she is using highly effective methods of contraception during the study treatment and for 21 days after stopping the treatment
total abstinence (when this is in line with the preferred and usual lifestyle of the patient)
female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks before taking study treatment
male partner sterilization (at least 6 months prior to study screening). For female patients on the study, the vasectomized male partner should be the sole partner for that patient
placement of an intrauterine device (IUD)
use of condom + spermicide
Use of oral (estrogen and progesterone), transdermal, injected, or implanted hormonal methods of contraception as well as hormonal replacement therapy
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note